BioSpecifics Technologies Corp. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe.
